4-溴-1-氯异喹啉 | 66728-98-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4-溴-1-氯异喹啉
• 中文别名: 1-氯-4-溴异喹啉
• 英文名称: 4-bromo-1-chloroisoquinoline
• 英文别名: 1-chloro-4-bromoisoquinoline
• CAS: 66728-98-1
• 化学式: C₉H₅BrClN
• mdl: MFCD00234469
• 分子量: 242.502
• InChiKey: HRWILRGBDZGABZ-UHFFFAOYSA-N

物化性质

• 熔点：
  97 °C (decomp)
• 沸点：
  328.8±22.0 °C(Predicted)
• 密度：
  1.673±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-1-chloroisoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-1-chloroisoquinoline
CAS number: 66728-98-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H5BrClN
Molecular weight: 242.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-1-氯异喹啉 在 盐酸 、 乙醇 、 硫酸 、 氨 、 氢溴酸 、 sodium acetate 、 copper(II) sulfate 、 钯 、 溶剂黄146 、 铂 、 sodium nitrite 、 三氯氧磷 作用下， 生成 四氢异喹啉
  参考文献：
  名称：

  Ochiai; Ikehara, Pharmaceutical Bulletin, 1954, vol. 2, p. 72,76

  摘要：

  DOI：
• 作为产物：
  描述：

  4-溴异喹啉 在 三氯乙腈 、 间氯过氧苯甲酸 、 三苯基膦 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 16.0h， 生成 4-溴-1-氯异喹啉
  参考文献：
  名称：

  使用 PPh3/Cl3CCN 区域选择性氯化喹啉 N-氧化物和异喹啉 N-氧化物

  摘要：

  已经开发了一种用于杂环 N-氧化物的区域选择性 C2-氯化的新方法。以PPh3/Cl3CCN为氯化试剂，以令人满意的收率顺利地获得了所需的N-杂环氯化物。反应以高效和选择性的方式在广泛的底物上进行，表现出优异的官能团耐受性。此外，该氯化反应可用于修饰有吸引力的配体和药物的 N-杂环支架。

  DOI：

  10.1002/ejoc.201501567
• 作为试剂：
  描述：

  (3-氨基苯基)砷酸 在 4-溴-1-氯异喹啉 作用下， 生成 [3-(4-bromo-[1]isoquinolylamino)-phenyl]-arsonic acid
  参考文献：
  名称：

  异喹啉系列中的砷。

  摘要：

  DOI：

  10.1021/ja01212a012

文献信息

• [EN] AURORA KINASE MODULATORS AND METHOD OF USE<br/>[FR] MODULATEURS D'AURORA KINASE ET PROCÉDÉ D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009117157A1

  公开（公告）日：2009-09-24

  The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式(I)的化合物，其中在此定义了A1-5和7-8，D'，L1，L2，R1，R3，R6-8，n和o，以及合成中间体，这些化合物能够调节枢纽激酶蛋白的活性，从而影响与枢纽激酶活动相关的各种疾病状态和病况。例如，这些化合物能够影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists
  作者：Raimo Saari、Jonna-Carita Törmä、Tapio Nevalainen

  DOI：10.1016/j.bmc.2010.11.059

  日期：2011.1

  Quinoline, isoquinoline, quinoxaline, and quinazoline derivatives were synthesized using microwave-assisted synthesis and their CB1/CB2 receptor activities were determined using the [35S]GTPγS binding assay. Most of the prepared quinoline, isoquinoline, and quinoxalinyl phenyl amines showed low-potency partial CB2 receptor agonists activity. The most potent CB2 ligand was the 4-morpholinylmethanone

  使用微波辅助合成法合成喹啉，异喹啉，喹喔啉和喹唑啉衍生物，并使用[ 35 S]GTPγS结合测定法测定其CB1 / CB2受体活性。大部分制备的喹啉，异喹啉和喹喔啉基苯胺均显示出低效的部分CB2受体激动剂活性。最有效的CB2配体是4-吗啉基甲酮衍生物（化合物40e）（-log EC 50  = 7.8；E max  = 75％）。异喹啉-1-基（3-三氟甲基-苯基）胺（化合物26c）是一种高效的CB2激动剂（-log EC 50  = 5.8; E max = 128％）。在这些研究中，没有发现明显的CB1受体激活或失活，除了40e表现出弱的CB1激动剂活性（CB1-log EC 50  = 5.0）。这些配体用作开发选择性CB2受体激动剂的新型模板。
• [EN] BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE<br/>[FR] COMPOSÉS PYRIMIDINES BICYCLIQUES INHIBITEURS DE PI3K SÉLECTIFS POUR P110 DELTA, ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010138589A1

  公开（公告）日：2010-12-02

  Formula (I) ((Ia) and (Ib)) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式（I）（（Ia）和（Ib））化合物，其中（i）X1为N且X2为S，（ii）X1为CR7且X2为S，（iii）X1为N且X2为NR2，或（iv）X1为CR7且X2为O，包括其立体异构体，互变异构体，代谢物和药用可接受盐，用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的疾病，如炎症，免疫和癌症。公开了使用公式（I）化合物进行体外，体内和体内诊断，预防或治疗哺乳动物细胞中的这类疾病或相关病理状况的方法。
• Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
  作者：Anupreet Kharbanda、Lingtian Zhang、Debasmita Saha、Phuc Tran、Ke Xu、Ming O. Li、Yuet-Kin Leung、Brendan Frett、Hong-yu Li

  DOI：10.1016/j.ejmech.2021.113660

  日期：2021.11

  is one of vital clinical interest. Despite various attempts, there is still no FDA-approved therapy to inhibit the TGFβ pathway. Major mainstream approaches involve impairment of the TGFβ pathway via inhibition of the TGFβRI kinase. With the purpose to identify non-receptor kinase-based inhibitors to impair TGFβ signaling, an in-house chemical library was enriched, through a computational study, to

  TGFβ对于上皮和神经组织的稳态、伤口修复和调节免疫反应至关重要。其失调与大量疾病有关，其中改变肿瘤微环境是重要的临床意义之一。尽管进行了各种尝试，但仍然没有 FDA 批准的抑制 TGFβ 途径的疗法。主要的主流方法包括通过以下方式损伤 TGFβ通路抑制TGFβRI激酶。为了识别基于非受体激酶的抑制剂以损害 TGFβ 信号传导，通过计算研究丰富了内部化学库，以消除 TGFβRI 激酶活性。针对在 TGFβ-Smad 依赖性转录控制下用萤火虫荧光素酶基因改造的细胞系筛选选定的化合物。结果表明具有酞嗪核心的分子对 TGFβ-Smad 信号传导具有中等效力。合成了一系列酞嗪化合物并评估其效力。最有希望的化合物 ( 10p ) 的 IC 50为 0.11 ± 0.02 μM，经证实在高达 12 μM 时无细胞毒性，选择性指数约为 112 倍。同时，10p证实使用蛋白质印迹可减少 Smad 磷酸化，而不显示对